Is EQ-5D-5L Better Than EQ-5D-3L? A Head-to-Head Comparison of Descriptive Systems and Value Sets from Seven Countries

ObjectiveThis study describes the first empirical head-to-head comparison of EQ-5D-3L (3L) and EQ-5D-5L (5L) value sets for multiple countries.MethodsA large multinational dataset, including 3L and 5L data for eight patient groups and a student cohort, was used to compare 3L versus 5L value sets for Canada, China, England/UK (5L/3L, respectively), Japan, The Netherlands, South Korea and Spain. We used distributional analyses and two methods exploring discriminatory power: relative efficiency as assessed by the F statistic, and an area under the curve for the receiver-operating characteristics approach. Differences in outcomes were explored by separating descriptive system effects from valuation effects, and by exploring distributional location effects.ResultsIn terms of distributional evenness, efficiency of scale use and the face validity of the resulting distributions, 5L was superior, leading to an increase in sensitivity and precision in health status measurement. When compared with 5L, 3L systematically overestimated health problems and consequently underestimated utilities. This led to bias, i.e. over- or underestimations of discriminatory power.ConclusionWe conclude that 5L provides more precise measurement at individual and group levels, both in terms of descriptive system data and utilities. The increased sensitivity and precision of 5L is likely to be generalisable to longitudinal studies, such as in intervention designs. Hence, we recommend the use of the 5L across applications, including economic evaluation, clinical and public health studies. The evaluative framework proved to be useful in assessing preference-based instruments and might be useful for future work in the development of descriptive systems or health classifications.

[1]  G Ardine de Wit,et al.  Dutch Tariff for the Five-Level Version of EQ-5D. , 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[2]  G. Bonsel,et al.  Health systems' responsiveness and reporting behaviour: Multilevel analysis of the influence of individual-level factors in 64 countries. , 2015, Social science & medicine.

[3]  G. Cesana,et al.  Comparing the performance of the standard EQ-5D 3L with the new version EQ-5D 5L in patients with chronic hepatic diseases , 2013, Quality of Life Research.

[4]  Zia Sadique,et al.  EQ-5D-5L versus EQ-5D-3L: The Impact on Cost Effectiveness in the United Kingdom. , 2018, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[5]  Nan Luo,et al.  Estimating an EQ-5D-5L Value Set for China. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[6]  Nan Luo,et al.  The EQ-5D-5L valuation study in Korea , 2016, Quality of Life Research.

[7]  P. Kind,et al.  A Comparison of United Kingdom and Spanish General Population Time Trade-off Values for EQ-5D Health States , 2001, Medical decision making : an international journal of the Society for Medical Decision Making.

[8]  Paul Kind,et al.  South Korean time trade-off values for EQ-5D health states: modeling with observed values for 101 health states. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[9]  Mark Oppe,et al.  A program of methodological research to arrive at the new international EQ-5D-5L valuation protocol. , 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[10]  E. van Doorslaer,et al.  Cut-Point Shift and Index Shift in Self-Reported Health , 2004, Journal of health economics.

[11]  R. Brooks,et al.  The EuroQol Group after 25 years , 2012, Springer Netherlands.

[12]  Jeffrey A. Johnson,et al.  Relative Efficiency of the EQ-5D, HUI2, and HUI3 Index Scores in Measuring Health Burden of Chronic Medical Conditions in a Population Health Survey in the United States , 2009, Medical care.

[13]  Michael Herdman,et al.  Development of the EQ-5D-Y: a child-friendly version of the EQ-5D , 2010, Quality of Life Research.

[14]  Nigel Rice,et al.  Analysis of the validity of the vignette approach to correct for heterogeneity in reporting health system responsiveness , 2011, The European Journal of Health Economics.

[15]  A. Pickard,et al.  Comparing responsiveness of the EQ-5D-5L, EQ-5D-3L and EQ VAS in stroke patients , 2014, Quality of Life Research.

[16]  R. Hays,et al.  Comparison of a generic to disease-targeted health-related quality-of-life measures for multiple sclerosis. , 1997, Journal of clinical epidemiology.

[17]  C. Gudex,et al.  Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study , 2012, Quality of Life Research.

[18]  P. Allen,et al.  Lognormal Distributions , 1945, Nature.

[19]  N. Luo,et al.  Chinese time trade-off values for EQ-5D health states. , 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[20]  A. Williams EuroQol : a new facility for the measurement of health-related quality of life , 1990 .

[21]  J. Richardson,et al.  Why do multi-attribute utility instruments produce different utilities: the relative importance of the descriptive systems, scale and ‘micro-utility’ effects , 2015, Quality of Life Research.

[22]  D. Marshall,et al.  Reliability and validity of the EQ-5D-5L compared to the EQ-5D-3L in patients with osteoarthritis referred for hip and knee replacement , 2015, Quality of Life Research.

[23]  C. Terwee,et al.  The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes. , 2010, Journal of clinical epidemiology.

[24]  C. Pantin Problems of Relative Growth , 1932, Nature.

[25]  G. Bonsel,et al.  The effect of adding a cognitive dimension to the EuroQol multiattribute health-status classification system. , 1999, Journal of clinical epidemiology.

[26]  J Hilden Prevalence-free utility-respecting summary indices of diagnostic power do not exist. , 2000, Statistics in medicine.

[27]  Brendan Mulhern,et al.  Valuing health‐related quality of life: An EQ‐5D‐5L value set for England , 2017, Health economics.

[28]  P. Dolan,et al.  Modeling valuations for EuroQol health states. , 1997, Medical care.

[29]  Mark Oppe,et al.  EuroQol Protocols for Time Trade-Off Valuation of Health Outcomes , 2016, PharmacoEconomics.

[30]  Aki Tsuchiya,et al.  Canadian Valuation of EQ-5D Health States: Preliminary Value Set and Considerations for Future Valuation Studies , 2012, PloS one.

[31]  J. Brazier,et al.  Effect of Adding a Sleep Dimension to the EQ-5D Descriptive System , 2014, Medical decision making : an international journal of the Society for Medical Decision Making.

[32]  Mark Oppe,et al.  Handling Data Quality Issues to Estimate the Spanish EQ-5D-5L Value Set Using a Hybrid Interval Regression Approach. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[33]  N. Devlin,et al.  EQ-5D and the EuroQol Group: Past, Present and Future , 2017, Applied Health Economics and Health Policy.

[34]  John Cairns,et al.  In search of a common currency: A comparison of seven EQ‐5D‐5L value sets , 2018, Health economics.

[35]  K. Perampaladas,et al.  Comparing EQ-5D valuation studies: A systematic review and methodological reporting checklist , 2013 .

[36]  Takashi Fukuda,et al.  Comparison of Value Set Based on DCE and/or TTO Data: Scoring for EQ-5D-5L Health States in Japan. , 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[37]  J. Hilden The Area under the ROC Curve and Its Competitors , 1991, Medical decision making : an international journal of the Society for Medical Decision Making.

[38]  D. Fairclough Design and analysis of quality of life studies in clinical trials , 2002, Quality of Life Research.

[39]  M. Thavorncharoensap,et al.  Measurement properties of the EQ-5D-5L compared to EQ-5D-3L in the Thai diabetes patients , 2015, Health and Quality of Life Outcomes.

[40]  J Alonso,et al.  BMC Medical Research Methodology BioMed Central Study protocol Protocol of the COSMIN study: COnsensus-based Standards for the selection of health Measurement INstruments , 2006 .

[41]  D. Fairclough Design and Analysis of Quality of Life Studies in Clinical Trials, Second Edition , 2010 .

[42]  David Parkin,et al.  What Determines the Shape of an EQ-5D Index Distribution? , 2014, Medical decision making : an international journal of the Society for Medical Decision Making.

[43]  Jing-jing Lv,et al.  Comparison between the EQ-5D-5L and the EQ-5D-3L in patients with hepatitis B , 2014, Quality of Life Research.

[44]  N. Ikegami,et al.  Estimating an EQ-5D population value set: the case of Japan. , 2002, Health economics.

[45]  Mark Oppe,et al.  Comparison of the underlying constructs of the EQ-5D and Oxford Hip Score: implications for mapping. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[46]  Mark Oppe,et al.  Quality Control Process for EQ-5D-5L Valuation Studies. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[47]  Gouke J. Bonsel,et al.  Evaluating the discriminatory power of EQ-5D, HUI2 and HUI3 in a US general population survey using Shannon’s indices , 2007, Quality of Life Research.

[48]  Yulia Blomstedt,et al.  Use of anchoring vignettes to evaluate health reporting behavior amongst adults aged 50 years and above in Africa and Asia – testing assumptions , 2013, Global health action.

[49]  P. Stalmeier,et al.  The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies. , 2006, Health economics.

[50]  N. Bansback,et al.  A Time Trade-off-derived Value Set of the EQ-5D-5L for Canada , 2015, Medical care.

[51]  Markus Lahtinen,et al.  Comparing the EQ-5D 3L and 5L: measurement properties and association with chronic conditions and multimorbidity in the general population , 2014, Health and Quality of Life Outcomes.

[52]  Nan Luo,et al.  The EQ-5D-5L index score is more discriminative than the EQ-5D-3L index score in diabetes patients , 2015, Quality of Life Research.

[53]  G. Bonsel,et al.  Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) , 2011, Quality of Life Research.

[54]  G. Bonsel,et al.  Feasibility, reliability, and validity of the EQ-5D-Y: results from a multinational study , 2010, Quality of Life Research.

[55]  J. Brazier,et al.  An Exploratory Study to Test the Impact on Three “Bolt-On” Items to the EQ-5D , 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[56]  A. Kasuya EuroQol--a new facility for the measurement of health-related quality of life. , 1990, Health policy.

[57]  T. Kohlmann,et al.  Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[58]  Kevin A. Rader,et al.  The EQ-5D-5L Improves on the EQ-5D-3L for Health-related Quality-of-life Assessment in Patients Undergoing Total Hip Arthroplasty , 2015, Clinical orthopaedics and related research.

[59]  K. Boye,et al.  Development of a disease-specific version of the EQ-5D-5L for use in patients suffering from psoriasis: lessons learned from a feasibility study in the UK. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.